229 related articles for article (PubMed ID: 17112809)
1. Sex differences in CYP3A activity using intravenous and oral midazolam.
Chen M; Ma L; Drusano GL; Bertino JS; Nafziger AN
Clin Pharmacol Ther; 2006 Nov; 80(5):531-8. PubMed ID: 17112809
[TBL] [Abstract][Full Text] [Related]
2. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
3. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
[TBL] [Abstract][Full Text] [Related]
4. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
5. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
6. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.
Gorski JC; Huang SM; Pinto A; Hamman MA; Hilligoss JK; Zaheer NA; Desai M; Miller M; Hall SD
Clin Pharmacol Ther; 2004 Jan; 75(1):89-100. PubMed ID: 14749695
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
Kharasch ED; Walker A; Hoffer C; Sheffels P
J Clin Pharmacol; 2005 Oct; 45(10):1187-97. PubMed ID: 16172184
[TBL] [Abstract][Full Text] [Related]
8. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
9. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
Masica AL; Mayo G; Wilkinson GR
Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
[TBL] [Abstract][Full Text] [Related]
10. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.
Chen M; Nafziger AN; Bertino JS
Drug Metab Dispos; 2006 Dec; 34(12):2079-82. PubMed ID: 16997909
[TBL] [Abstract][Full Text] [Related]
11. The effect of hormone replacement therapy on CYP3A activity.
Gorski JC; Wang Z; Haehner-Daniels BD; Wrighton SA; Hall SD
Clin Pharmacol Ther; 2000 Oct; 68(4):412-7. PubMed ID: 11061581
[TBL] [Abstract][Full Text] [Related]
12. Single plasma sampling to predict oral clearance of CYP3A probe midazolam.
Zhu B; Ou-Yang DS; Cheng ZN; Huang SL; Zhou HH
Acta Pharmacol Sin; 2001 Jul; 22(7):634-8. PubMed ID: 11749829
[TBL] [Abstract][Full Text] [Related]
13. The interaction between St John's wort and an oral contraceptive.
Hall SD; Wang Z; Huang SM; Hamman MA; Vasavada N; Adigun AQ; Hilligoss JK; Miller M; Gorski JC
Clin Pharmacol Ther; 2003 Dec; 74(6):525-35. PubMed ID: 14663455
[TBL] [Abstract][Full Text] [Related]
14. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
15. Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis.
Hu ZY; Zhao YS
Drug Metab Dispos; 2010 May; 38(5):817-23. PubMed ID: 20164111
[TBL] [Abstract][Full Text] [Related]
16. Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics.
Rogers JF; Morrison AL; Nafziger AN; Jones CL; Rocci ML; Bertino JS
Clin Pharmacol Ther; 2002 Dec; 72(6):711-7. PubMed ID: 12496752
[TBL] [Abstract][Full Text] [Related]
17. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam.
Kashuba AD; Bertino JS; Rocci ML; Kulawy RW; Beck DJ; Nafziger AN
Clin Pharmacol Ther; 1998 Sep; 64(3):269-77. PubMed ID: 9757150
[TBL] [Abstract][Full Text] [Related]
18. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam.
Palkama VJ; Ahonen J; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 1999 Jul; 66(1):33-9. PubMed ID: 10430107
[TBL] [Abstract][Full Text] [Related]
19. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam.
Shord SS; Chan LN; Camp JR; Vasquez EM; Jeong HY; Molokie RE; Baum CL; Xie H
Br J Clin Pharmacol; 2010 Feb; 69(2):160-6. PubMed ID: 20233179
[TBL] [Abstract][Full Text] [Related]
20. The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe.
Ma JD; Nafziger AN; Rhodes G; Liu S; Gartung AM; Bertino JS
J Clin Pharmacol; 2006 Jan; 46(1):103-8. PubMed ID: 16397289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]